INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Corporate insider
KE

Karas Eric

Chief Commercial OfficerCIK 0001951287

EDGAR filingsOpen in network
Disclosed transactions3
Buys / sells0 / 1
Max Insider Score23
Connections1with evidence

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
3
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M—
25.0K sh
Jun 12, 2026Jun 12, 2026
traded Jun 12, 2026
+0dSEC FORM 4

Evidence

Verified connections

  • Insider ofevidence
    ARS Pharmaceuticals, Inc.Chief Commercial Officer · Jun 12, 2026
23
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Open-market sale · 10b5-1 plan
SELL
$250K
25.0K sh
Jun 12, 2026
Jun 12, 2026
traded Jun 12, 2026
+0d
SEC FORM 4

Evidence

11
KE
Karas EricChief Commercial Officer
SPRYARS Pharmaceuticals, Inc.
Option exercise · 10b5-1 plan
M$38K
25.0K sh
Jun 12, 2026Jun 12, 2026
traded Jun 12, 2026
+0dSEC FORM 4

Evidence